![](/img/cover-not-exists.png)
PCN197 - COST UTILITY ANALYSIS OF FIRST-LINE PACLITAXEL WITH CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB VERSUS PEMETREXED WITH CARBOPLATIN FOLLOWED BY MAINTENANCE PEMETREXED IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER IN LEBANON
Tfayli, A., Elias, F., Farhat, F., Slim, R., Hallal, Z., Maatouk, L., Ibrahim, A., Anan, I.Volume:
21
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2018.09.279
Date:
October, 2018
File:
PDF, 378 KB
english, 2018